CA
NZ
UK
AU
IND
US
ARS Pharmaceuticals undergoes a leadership transition, marking a new chapter for the biotech firm. The company has announced a shift in its executive team, signaling potential strategic adjustments ahead.
CalciMedica Inc. (NASDAQ: CALC) has expanded its board of directors to eight members. This move is part of the company's efforts to strengthen its governance and leadership in the healthcare sector. The expansion is expected to bring new perspectives and expertise to the board.
Keenova Therapeutics plc disclosed on July 8, 2026 that its Phase 3 investigation of XIAFLEX for plantar fibromatosis met the trial’s primary and key secondary objectives. The announcement follows a regulatory filing that underscores both efficacy signals and a tolerability record consistent with existing …
Ovid Therapeutics (NASDAQ: OVID) announced a change in its financial leadership, naming Charles Carter as its new Chief Financial Officer. The move follows the departure of Jeffrey Rona, who held multiple executive roles, including principal financial and accounting officer. His prior experience includes CFO …
AdaptHealth Corp. (NASDAQ: AHCO) has announced plans to redeem all of its outstanding senior notes, a move that is expected to reduce the company's debt and improve its financial health. This decision is part of the company's ongoing efforts to optimize its capital structure …
Aura Biosciences, Inc. (NASDAQ: AURA) has taken steps to enhance its governance structure by expanding its board of directors. The company increased its board membership from six to seven with the addition of Jeremy Bender, Ph.D. As an independent director. This move aligns with …
Evolus, Inc. (NASDAQ: EOLS) disclosed a licensing arrangement with Swiss partner IBSA Institut Biochimique SA on July 7 2026. The deal grants Evolus sole authority to develop, market and distribute the Profhilo injectable hyaluronic acid formulation across the United States for aesthetic and dermatological …
Moderna Inc. (NASDAQ: MRNA) has expanded its board with the appointment of Michael McDonnell, a seasoned financial executive with deep experience in the biopharmaceutical sector. The move reflects the company’s focus on strengthening governance as it navigates post-pandemic growth challenges. From August 2020 until …
Privia Health Group, Inc. (NASDAQ: PRVA) filed a notice indicating a shift in its board composition. Effective July 6, 2026, Shawn Morris stepped down from his role as a director and from the board’s compliance committee. The announcement clarifies that his exit does not …
Amphastar Pharmaceuticals confronts heightened regulatory scrutiny after its subsidiary received an FDA warning letter. The development underscores compliance risks for the drugmaker’s manufacturing operations.
Please wait processing your request...